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Working Together to Eliminate Hepatitis B and C
John W. Ward, MD
Program Director, Viral Hepatitis Elimination, Task Force for Global Health
Senior Scientist, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention 
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Hepatitis B and Hepatitis C Viruses Are Blood Borne Infections
Sanyal AJ, Terrault NA, Lindor KD, et al. Zakim & Boyer’s Hepatology A Textbook of Liver Disease 7th ed. 2017, 428-445
Meeting of the International Task Force for Disease Eradication, June 2017. Wkly Epidemiol Rec. 2017 Sep 15;92(37):537-56
Transmission  
● Exposures to contaminated blood (health care, substance abuse, perinatal)
● Sexual (greatest risk for HBV) 
Chronic infection causes most morbidity and mortality
● 20%–25% lifetime risk of premature death from liver cirrhosis and cancer or 
extrahepatic disease
● HCV increases other disease risks (e.g., type 2 diabetes, non-Hodgkins lymphoma) 
Prevention
● Hepatitis B vaccination 
● Reduce viral exposures—universal precautions, safe injection, safer sex   
● HBV and HCV testing, care and treatment; curative for HCV
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HBV and HCV Are Major Global Health Threats 
In 2000, 1.28 million deaths per year 
● HBV: 884,000, HCV: 420,000
● HBV and HCV cause 50% of all 
primary liver cancer deaths globally
Globally, 328 million people infected
● HBV: 257 million
 2/3 living in Western Pacific or Africa
 Major risk: perinatal or horizontal contact 
among young children
● HCV:  71 million
 2/3 living in Europe, south  Asia, north Africa 
 Major risk: healthcare-associated transmission





While Other Diseases Are Declining, 

















Hepatitis Tuberculosis HIV Malaria
Global Burden of Selected Diseases, 2000–2015  
www.who.int/hepatitis/publications/global-hepatitis-report2017/en/
www.who.int/hepatitis/strategy2016-2021/ghss-hep/en
HBV and HCV 
cause 96% of 
mortality from all 
forms of viral 
hepatitis
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Global and U.S. Goals for Elimination of HBV and HCV 
as Public Health Threats by 2030 
UN SDG called on global community to “combat hepatitis” 
In 2016, World Health Assembly endorsed WHO global 
elimination goals for HBV and HCV 
● By 2030, 90% reduction in new infections and 65% reduction in deaths
● WHO encourages development of national goals
In 2017, U.S. IOM (NAS) developed U.S. elimination goals 
and recommended actions by 2030 
● Hepatitis B: 100% reduction in new cases in children age under 5 years 
50% reduction in deaths
● Hepatitis C:   90% reduction in new cases
65% reduction in deaths 
SDG: Sustainable development goals                                  NAS: National Academy of Sciences nationalacademies.org/hmd/Reports/2017.aspx
www.who.int/hepatitis/publications/global-hepatitis-report2017/en/                                     www.who.int/hepatitis/strategy2016-2021/ghss-hep/en
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Hepatitis B Vaccine is the Cornerstone for HBV Elimination




































Hepatitis B vaccine 3rd dose Hepatitis B vaccine birth dose
Chronic infections
Hepatitis B Vaccine Coverage and Number of 
Lifetime Chronic Infections by Year of Birth, 
Western Pacific Region, 1990–2014 
Verified (19)
Programme improvements required (6)
Serosurvey with <1% but not submitted (3)
Serosurvey planned (6)
Awaiting results of serosurvey (1)
Under review for verification (1)
Data not available (1)
Western Pacific Region achieved goal of <1% 
of children with HBV by 2017
Cases
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Vaccine-based Strategies to Eliminate HBV Transmission 
in the United States 
HBIG: Hepatitis B immunoglobulin
Abara WE, Qaseem A, Schillie S, et al. Ann Intern Med. 2017;167(11):794-804       Schillie S, Vellozzi C, Reingold AR, et al. MMWR 2018 Jan 12;67(1):1–31
Prevent mother-to-child transmission
● Increase HepB birth-dose coverage from 72% 
to 90% or higher
● Case management to assure HBV exposed new-
borns receive vaccine/HBIG at birth and follow-up 
Test HBsAg+ mothers for HBV DNA viral 
load to guide maternal antiviral therapy 
Maintain childhood and adolescent HepB vaccine coverage >90%
Improve vaccination of at-risk adults 
.
10
Reducing HBV Deaths by 50% in the United States by 2030 
850,000–2.2 million people with chronic HBV
● 50% are Asian/Pacific Islanders (API); sixfold
mortality risk for API
● HBV testing recommended for persons from 
countries with >2% prevalence (i.e., Asia, Africa)
Long term therapy decreases mortality 
by 50-60%  
60% aware of their infection, and only ~15% 
recommended for treatment receive it  
● Using culturally appropriate outreach, community 
coalitions can increase testing and linkage to treatments  
HBV Linkage to Care Cascade, 



























Schillie S, Vellozzi C, Reingold AR, et al. MMWR 2018 Jan 12;67(1):1–31;  Ly KN, Xing J, Klevens RM, et al. Clin Infect Dis. 2014 Jan;58(1):40-9; Abara WE, 
Qaseem A, Schillie S, et al. Ann Intern Med. 2017 Dec 5;167(11):794-804; Harris AM, Schoenbachler BT, Ramirez G, et al. Public Health Rep. 2016 May-
Jun;131 Suppl 2:20-8;  Lok AS, McMahon BJ, Brown RS Jr, et al. Hepatology. 2016 Jan;63(1):284-306; Harris AM, Chandrasekar E, Wang S, et al. 
Hepatology 2016, Abstract 1773 aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.28800 .
11
HCV Can Be Cured
Ward JW & Holtzman DA. Hepatitis C. In Zakim & Boyer’s Hepatology A Textbook of Liver Disease 7th ed. 2017, 428-445
van der Meer AJ, Veldt BJ, Feld JJ, et al. JAMA. 2012 Dec 26;308(24):2584-93
3.5 million people with HCV in U.S. 
● 81% born 1945–1965 and 70% have 
moderate-severe liver disease
● Birth year cohort testing recommended 
by CDC and USPDTF
HCV treatment - oral meds for 8–12 weeks
Over 95% treated are cured
HCV cure reduces liver related 
mortality by 93%
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By 2030, Reduce HCV Deaths by 65% in the United States
While 60% of persons aware of HCV diagnosis, only 22% treated 
In 2016, HCV mortality declined 7% 
Certain interventions increase 
testing and linkage to care 
and treatment 
Drug costs have declined and 
are cost-saving
● Many payers continue to restrict access 
● In 2017, HCV prescriptions fell 26% 
for Medicaid and 40% for private payers  
van der Meer AJ, Veldt BJ, Feld JJ, et al. JAMA. 2012 Dec 26;308(24):2584-93;  Chhatwal J, He T, Hur C, et al. Hepatol. 2017 Jun;15(6):827-837; Barua S, 























Annual Number of U.S. Deaths Due to 
Hepatitis C, 2003–2016 
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“As Native People and as Cherokee Nation Citizens, We Must Keep 
Striving to Eliminate Hepatitis C.” 
Mera J, personal communication  
Mera J, Vellozzi C, Hariri S, et al. MMWR. 2016 May 13;65(18):461-6
American Indians have highest HCV incidence 
and mortality 
Cherokee Nation launched elimination program in 2015 
● Universal HCV testing for patients 20–69 yrs.  
● Training and electronic tools to prompt testing   
● Care managed by mid-level providers (e.g., pharmacists)
● Health system strategies to pay for testing and treatment 
● Contact tracing to identify new HCV infections 
● Partnerships with CDC, state and local health, NGOs 
Chief Bill John Baker
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Native People and Cherokee Nation Citizens Have Made 
Substantial Progress to Eliminate Hepatitis C 
Mera J, personal communication  



















Percent of Native People and Cherokee Nation Citizens Reaching Each Step 





When Neededof All Adults Initiated Achieved 
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New Concern: 
Rising HCV Incidence Related to the Opioid Epidemic
Zibbell JE, Asher AK, Patel RC, et al. Am J Public Health. 2018 Feb;108(2):175-181
www. cdc.gov/hepatitis; https://www.cdc.gov/hepatitis/statistics/index.htm 
Suryaprasad AG, White JZ, Xu F, et al. Clin Infect Dis. 2014 Nov 15;59(10):1411-9
In 2016, 41,200 new HCV 
infections in U.S. 
80% related injection drug use
Threefold increase since 2010
● Adults less than 40 yrs. old, white, 
suburban and rural – esp. Appalachian, 
Midwestern, New England states
Parallel increases in injection of 
prescription opioids and heroin 
Incidence of Acute Hepatitis C 





























Elimination of HCV Transmission Requires 
Greater Access to Prevention Services
SSP: Syringe services program  Platt L, Minozzi S, Reed J, et al. Cochrane Database Syst Rev. 2017 Sep 18;9;  Canary L, Hariri S, Campbell C, et al. Clin
Infect Dis. 2017 Aug 1;65(3):514-517; Fraser H, Zibbell J, Hoerger T, et al. Addiction. 2018 Jan;113(1):173-182;  Campbell CA, Canary L, Smith N, et al. 
MMWR 2017 May 12;66(18):465-469
Access to safe injection equipment and treatment for 
drug addiction can lower transmission risks by over 70% 
Add HCV therapy, cure as prevention, 
can reduce infection and 
transmission by 90%
Areas with high HCV incidence 
have low SSP coverage
● Only three states have laws 
supporting access to safe injections 
● 24 state Medicaid programs deny HCV treatment for recent or current PWID 
Only 20% of people 15–29 
years old with HCV, live 
within 10 miles of one of 
270 syringe service 
programs
Map of Syringe Services Programs and HCV Infected 




New Concerns: HCV Infected Mothers and Newborns 
Adapted from: Koneru A, Nelson N, Hariri S, et al. MMWR 2016 Jul 22;65(28):705-10
Increased HCV among pregnant women 
In 2014, 1 of 308 U.S. births were 
to HCV-infected mothers
● 1 of 63 in Kentucky (high incidence state)
6–12% transmission risk for infants
In 2018, perinatal HCV 
surveillance started 
Consider policies for routine HCV 












2011 2012 2013 2014
Year of Infant Birth
1 of 63 births in KY
Rates of Infants Born to HCV-Infected 













“Any National Campaign to Eliminate Hepatitis C Would Almost 
Certainly Involve Prisons.” —
QALY: Quality-adjusted life year 
Canary L, APHA 2016; CDC unpublished data. Hochstatter KR, Stockman, L, Holzmacher R, et al. Health Justice. 2017 Oct 30;5(1):10;
He T, Li K, Roberts MS, et al. Ann Intern Med. 2016 Jan 19;164(2):84-92. www.nytimes.com/2018/03/15/us/hepatitis-c-drugs-prisons.html 
Multiple prison systems
High HCV prevalence
Testing and treatment are 
effective prevention
● Reduces deaths and 
prevents new infections in 
the community upon release
● $20–29K per QALY 
Lawsuits in 10 states for 






























Number and Percent of HCV Antibody Positivity, Federal and 
State Facilities, 2012–2015
March 18, 2018 
19
Research and Evaluation Can Improve HBV and HCV 
Elimination Strategies  
Liang J. & Ward JW. N Engl J Med. 2018 Mar 29;378(13):1169-1171
Technical 
● HCV vaccine can reduce high HCV incidence among new injectors
● Point-of-care tests can simplify testing for current and recurrent HCV  
● Next generation HBV therapies can improve treatment outcomes  
Operational 
● Simplified care models can expand access in resource-constrained settings   
● Field trials of HCV Cure as Prevention strategies for people who inject drugs 
Evaluation and data
● Systems to provide data to evaluate quality and monitor progress toward elimination  
20
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San Francisco Department of Public Health
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Hepatitis B in San Francisco
A Nishimura, Personal Communication, March 9 2018
www.city-data.com
In 2016, there were 819 (95.6/100,000) newly confirmed                                    
cases of chronic hepatitis B (CHB) 
About 88% of cases of CHB are among 
Asian/Pacific Islanders (A/PI)
● Many people of A/PI ancestry are foreign born, 
particularly in China
● Death rates from CHB are highest for A/PI 
Multiple barriers (e.g., social or cultural, 
educational, language) hinder access to 
recommended prevention interventions
White alone






Success in Preventing Perinatal Transmission of Hepatitis B
L Afu-Li, Personal Communication, February 28, 2018
The Perinatal HBV vaccination program in San Francisco identifies and 
tracks pregnant, HBV+ women and ensure their infants are given the 
birth dose vaccine upon birth. 
Since 2011, no new perinatal HBV infections 
● Each year, 140–180 infants born to HBV+ women
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Hep B Free Bay Area
Mission: To turn San Francisco into the first HBV-free city in the nation
● Founded in 2007 as a public–private partnership
● Launched media campaign to raise awareness in 2010
25
Hep B Free Bay Area Efforts Led to Increased HBV Testing, Reports
Nishimura A, Unpublished Data, 2018
Between 2012–2014, 
10,000 HBV tests performed in 
community settings 
● Supported by CDC grant
In 2015, business initiative 
launched, creating Business 
Honor Roll 
In 2016, HBV linkage to care phone 
line launched, in multiple languages 
2017 San Mateo County expansion
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Hepatitis C in San Francisco
In 2016, there were 1,008 (117.6/100,000) newly confirmed cases 
of hepatitis C 
● 30% African American
About 2.5% of the 
population 
(or 22,000 residents) 
have been infected 
with HCV 
An estimated 12,000 
people currently 
infected with HCV 
Facente SN, Grebe E, Burk K, et. al. PLOS ONE 13(4): e0195575 
A Nishimura, personal communication, Feb 2018
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HCV Prevention and Testing Infrastructure in SF
Syringe exchange
 7 days/week availability
 Secondary exchange network
Naloxone Access
HIV and HCV Testing
Low-threshold methadone 
and buprenorphine
Referrals to drug treatment
= syringe access 
and 
disposal sites
Map of San Francisco Syringe Access and Disposal Locations 
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End Hep C SF Partnerships and Strategic Plan
29
Representation of Impacted Communities:
End Hep C SF Coordinating Committee
Joanne Kay


























End Hep C SF Community Engagement Strategies
Photos: End Hep C SF, Community meeting 8/3/17
“New Treatments Have Changed the Game” Campaign 2015
● Video installment, 2018
“Tales from the Cured” community meeting, August 3, 2017
“Get Cured, Stay Cured” community meeting, March 8, 2018
Peer-based HCV linkage program, 2018
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End Hep C SF 
Community-based Testing Strategies
HIV/HCV rapid testing sites
● Syringe exchange programs
● Shelters
● Single-room occupancy hotels
● Residential drug treatment intake


















2015 Q1 2015 Q2 2015 Q3 2015 Q4 2016 Q1 2016 Q2 2016 Q3 2016 Q4 2017 Q1 2017 Q2 2017 Q3 2017 Q4
Rapid Antibody HCV Testing, 1/1/15–12/31/17,
San Francisco Department of Public Health
Reactive Total Tests Linear (Total Tests)
Launch of 






Community-based Screening Antibody Reactivity by Risk Factor
IDU: Injection drug use
Raganold, E. SFDPH unpublished data, 2018
Community-based HCV Rapid Tests







IDU ever 92% 478
Ever stimulant smoking 84% 436
Homeless (in past 12 months) 72% 374
Baby Boomer 43% 225
Ever incarcerated 24% 125
In 2017, total 




Primary Care-based HCV Treatment Access: Strategy for Scale
Facente SN, Burk K, Eagen K, et al. Infectious Disease Clinics of North America (in press) 
As of February 2016, 3 components of the capacity-building HCV 
treatment initiative for primary care physicians in the San Francisco 
Health Network
1. In-person training
2. eReferral consultation services
3. Individualized clinic technical assistance
Pre- and Post-Intervention Analysis









Total Patients Treated* 143 8.9 435 18.9 112%
Total Clinics Represented 
among Treated 5 n/a 12 n/a 140%
*Five treated cases had no listed PCP
35
HCV Treatment Access Beyond Traditional Clinic Settings: 
Strategy for Impact









Opiate Treatment Outpatient Program (UCSF) 136 120 August 2016
San Francisco County Jail 100 77 March 2017
Residential Drug Treatment (HealthRIGHT 360) 69 67 January 2016
Syringe Exchange (San Francisco AIDS Foundation) 19 10 August 2017
Street Medicine 12 7 May 2016
Shelter 10 10 Dec 2016
Magnet (Gay Men’s Sexual Health Clinic, SFAF) 4 1 June 2017
Total 350 292
Discussions underway to start treatment in inpatient settings, and 
to restart treatment at the shelter and jail
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HCV Resources Needed
Resources for surveillance to track negative test results, HCV cures
Additional funding for HCV testing and linkage services for 
vulnerable populations
HCV-specific nursing in high-prevalence clinics
HCV treatment access for jail-based and privately funded populations
Sustainable funding to support the End Hep C SF initiative 
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Placing New Mexico on The Path to HCV Elimination
Kimberly Page, PhD, MPH
Professor and Division Chief
Epidemiology, Biostatistics and Preventive Medicine
University of New Mexico Health Sciences Center
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High Hepatitis C Virus (HCV) Burden in NM
NMDOH: New Mexico Department of Health         *Confirmed and probable past or present HCV cases        ++ CDC Enhanced surveillance sites, US 2015
#Denniston et al. 2014; Edlin et al, 2015; Chak et al. 2011; Varan et al. 2014; Strehlow et al.2012; Brillman et al. J 2002; Neumeister et al. 2007
High prevalence and incidence 
of HCV 
● 2016 NMDOH*: 53,286 unique individuals 
with a positive test for HCV in 2016
● 280.7/100,000 (vs. US 52.3/100,000)++
Modeling by using multiple 
population size sources:#
● 53,107 people with HCV infection
NM IBIS 2015 
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Disproportionate Rates of Liver Disease Morbidity 
And Mortality in New Mexico




HCC incidence or 
mortality (2012) 8.6 6.2 
HCV-related mortality 
(2104) 10.0 6.0
HCC: Hepatocellular carcinoma  
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Increasing HCV in Young Adults in NM
Young adults: Under 30 years of age
ibis.health.state.nm.us/  accessed on 03/04/2018 
Following national trends, HCV is 
increasing among young adults 
● Significant opioid use in NM
Acute HCV cases detected has 
increased by 40% since 2010
● Majority report injection drug use 
exposure as likely transmission route
● VÁLE Study of young PWID:
 65% have been exposed (anti-HCV positive)
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Setting HCV Elimination Goals in NM: NM-HEP
PWID: People who inject drugs
HCV Elimination Collaborative, initiated in 2016. Stakeholders include: 
● NM Department of Health 
● University of New Mexico Health Sciences Center, including Project ECHO, and 
Division of Epidemiology, Biostatistics, and Preventive Medicine
● NM Department of Corrections
● Indian Health Service
● Tri-Core Laboratories 
Agreed to adopt an “incremental approach” with a targeted 
population: Medicaid population was prioritized 
● Other groups identified to focus on: the baby-boomer cohort, children, PWID, 
American Indians, homeless, and incarcerated populations to inform the “whole”
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Program Development, Structure and Workgroups 
of HCV Elimination Collaborative
Steering Committee
Research and 
Strategic Information HCV Prevention
HCV Testing and 
Linkage to Care




Advocacy, Policy, and Practice
Strategic Planning
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Factors that Contribute to Feasibility of HCV Elimination in NM
1. Data: Informed by surveillance and research
2. HCV treatment access: Equitable policies to facilitate treatment
3. Disseminated care model to reach rural areas of NM: Project ECHO
4. Extensive prevention and treatment for PWID: Evidence-based 
approaches that reduce incidence
5. Department of Corrections: Programs in place
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1. Data, Research, and Strategic Information
NMDOH: New Mexico Department of Health                                                           PWID: People who inject drugs
UNM: University of New Mexico 
Surveillance 🔎🔎
● NMDOH HCV reporting and surveillance of under 30-year-olds
● Harm reduction program supported by the NMDOH
Research ⚛
● The VÁLE! Study (1U18PS004568; PI K. Page): Assesses HCV epidemiology and 
access to prevention and care in young adult (<30 yrs) PWID in two counties 
● HERO study: HCV treatment uptake in PWID in two clinics at UNM
Registry ✎
● Precedent: Cancer Registry, UNM is custodian for NMDOH
● Data exists so we are assessing feasibility
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2. HCV Treatment Is Highly Accessible in NM
*Harvard Center for Health Law and Policy Innovation
No. of NM Medicaid members treated and percent approval of authorizations at year end for 2014 through 2017 
F1-F4: Metavir fibrosis stages 1-4. DC: Decompensated cirrhosis. HCC: Hepatocellular carcinoma
NM gets an “A” * 
47% of NM population covered 
by Medicaid
● Medicaid treatment guidelines as 
of 2017: no restrictions by disease 
stage, provider type, or abstinence
HCV treatment has increased 



























2014 2015 2016 2017
Members Treated % Approval of Authorization for HCV Treatment
F1-F4, 
DC, HCC All HCV 
F2-F4, 
DC, HCC
Percent Authorized for Treatment and 
Number Treated, NM, 2014–2017
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3. Project ECHO: Building Capacity To Disseminate HCV Health Care 
and Reduce Health Disparities
DAA: Direct-acting antivirals
41 sites in HCV teleECHO clinics
● ECHO has enabled widespread ramp up of DAA 
treatment, provider knowledge and experience for 
working with patients in rural areas.
Other teleECHO capacity
● Integrated Addiction and Psychiatry program: 
99 providers at 41 sites
● UNM Opioid ECHO: 69 providers at 46 sites
● Indian Health Service: 37 clinics at 9 IHS/Tribal sites 
● Community health worker: 64 providers at 43 sites
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4. HCV Prevention and Treatment: Reduce and Prevent HCV 
In High Risk Groups
SSP: Syringe services program 
PWID: People who inject drugs
Large population of people at risk of HCV due to injection drug use 
● Using SSP program data and capture-recapture methods, we estimate 
20,150 active PWID in New Mexico in 2016 
● At least 60% have HCV, or a minimum of 12,090 persons
Programs, policies and research supported and implemented by public 
health, academic and community partners
● NM Department of Health 
● UNM Health Sciences Center: Epi-Biostat-PM, Truman Health Services, Addictions 
and Substance Abuse Program, Project ECHO
● Mountain Center, El Centro, Healthcare for the Homeless, Southwest Care
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Extensive Support and Breadth of Prevention Services
Extensive harm reduction services including: Syringe Services Program 
(SSP), education, health referrals, and naloxone distribution
● Yearly distribution of ~6 million syringes through 2017, including rural areas
● With new polices passed in 2017, over 9 million syringes will be distributed in 2018
Medically Assisted Treatment (MAT) programs
● Public and private services
● Project ECHO Integrated Addictions and Psychiatry Program has expanded training 
for certified buprenorphine providers in underserved areas 
But –
● Wait lists for MAT 
● Other drug use, including methamphetamine, is prevalent
49
SSP Service Points in New Mexico




HCV Treatment for PWID 
For people who inject drugs (PWID), HCV treatment can break the 
cycle of transmission
● Estimated 20,150 active PWID in NM in 2016
● At least 60% have HCV, over 12,000 people 
90% of young adult PWID report having medical insurance, making 
HCV treatment accessible in this high risk group
● However, compared to older PWID, they are not accessing treatment
New methods needed to educate and deliver treatment to this group
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HCV Treatment for PWID… and more research needed
Ongoing treatment research –
HERO Study
● HCV treatment in active PWID at 
community and MAT sites, randomized 
to mDOT or Patient Navigation
HCV vaccine research –
VIP Study – results in Nov. 2018
HERO is funded  by Patient-Centered Outcomes Research Institute (PCORI) Award HPC-1503-28122 with additional support by Gilead Sciences, Quest 
Diagnostics, Monogram Biosciences, and OraSure Technologies
VIP is funded by NIAID/DMID HHSN2662040074C, Clinicaltrial.gov ID: NCT01436357
52
5. New Mexico Corrections Department
Currently 7,327 people incarcerated in NM (February 2018) 
● 6,524 men; 803 women 
Universal screening for HCV at entry 2009–2017
● 27,994 unique individuals were screened for anti-HCV
● 11,514 anti-HCV positive: 41.13%
● 1,540 found to be anti-HCV positive while incarcerated
HCV treatment: 106 patients (August 1, 2015 to December 30, 2017)
Prevention: New Mexico Peer Education Project
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Strategic Planning for HCV Elimination 
Strategic Planning Committee representing academia, public health 
department, and community, drafting strategic plan, including 
● Defined measures, strategies, and indicators of success 
● Metrics for each workgroup 
New Mexico HCV elimination website in development
Financing:  This remains a large gap and challenge for our overall effort
54














By 2030, We Aim To: 
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National Progress toward Hepatitis B and 
Hepatitis C Elimination in Australia
Benjamin C. Cowie MBBS, PhD, FRACP
Director, WHO Collaborating Centre for Viral Hepatitis, Doherty Institute, 
Physician, Royal Melbourne Hospital and University of Melbourne
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Percentage Change in Age-standardised Cancer Mortality Rates, 
Australia, 1982–2014 
GBD: Global burden of disease                                                                       www.aihw.gov.au/getmedia/f6e80a97-a8a3-4709-bcc3-ea3d76175c31/18302.pdf 
Brown CR, Allard NL, MacLachlan JH & Cowie BC. Int Med J 2017;47(5);  GBD 2016 Causes of Death Collaborators. Lancet. 2017 Sep 16;390(101000
● In 2016, estimated 2% of Australians living 
with chronic viral hepatitis
● GBD 2016 mortality estimates for Australia
 Chronic hepatitis B – 900 deaths
 Chronic hepatitis C – 1,100 deaths
 HIV/AIDS – 74 deaths
● Liver cancer is now the 6th most common 
cause of cancer deaths of Australians
● Low 5-year survival – 16%, compared 
with 67% for all cancers
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How Can We Increase Access to Treatment And Care for Chronic 
Viral Hepatitis to Reverse The Increasing Mortality Burden?
DAA: Direct-acting antivirals OECD: Organisation for Economic Co-operation and Development
Dore GJ. & Grebely, J. J Hepatol. 2017 Aug;67(2):419-420
Example: Innovative financing solutions for HCV DAAs
● After repeated rejections and intense negotiations between pharmaceutical 
companies and the Australian Government, the first DAA regimens were listed on 
national pharmaceutical benefits scheme (PBS) 
● For treatments listed on the PBS, for each month of treatment, the total 
co-payment by the patient is USD $30; for concessional patients, it is $5
● Competitive pricing agreed with pharmaceutical companies; innovative risk-share 
‘cap’ arrangement
 Cost to the PBS is USD $6,000–$7,500 per course
 Lowest price-per-cure in the OECD – e.g., some European national health insurance 
programs paid more than 10 times as much per cure as Australia
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Comparative Prices of Sofosbuvir and Daclatasvir
Per 12-week Course
Hill, A. Presented at: World Hepatitis Summit, São Paulo, 2017
Andrew Hill at World Hepatitis 
Summit, 2017:
Huge variation in list prices –
- <$   100 in India and Egypt 
- $  6,000 in Australia
- $50,000 in France
- $77,000 in the UK
- $96,000 in the USA 
59
How Has This Financing Arrangement Influenced Models of Care?
CHC: Chronic hepatitis C
PBS: Pharmaceutical benefits scheme 
Strong financial incentive for Government to liberalise access to CHC care
● Any doctor can prescribe—not restricted to specialists
 Most scripts now written by nonspecialists
● Any stage of liver disease
● Treatment in prisons, treatment of active injectors, re-treatment all funded
● Funding for workforce training, community groups, surveillance and monitoring
● Still some gaps—regional areas, Indigenous Australians
How does this compare with CHB?
● Treatment on PBS, monitoring (with some restrictions) also fully reimbursed
● Specialist model—training and certifications for General Practitioners
● Limited community awareness and engagement
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Need to Ensure Continued Focus on Prevention
Keep Downward Pressure on Incidence While Reducing Prevalence 
NSP: Needle syringe programs
Harm reduction relatively strong in Australia
● Funded needle and syringe programs, opiate replacement therapy
● Medically supervised and safe injecting rooms in Sydney and soon in Melbourne
● Funded peer-support organizations for people who inject drugs
● No NSPs in prisons
● Need to ensure continued focus on ‘turning off the tap’
Free hepatitis B vaccination in addition to infant program
● Broad range of funded indications on a jurisdictional basis
● Supported by subsidized or free primary care via national insurance
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Australian Cascade of Care for Chronic Hepatitis B
Hepatitis B Mapping Project: 




the 95% goal.  
However, for people 
living with CHB, 
over 80% are not in care 
and little to no 
improvement 
since 2014.  
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Australian Cascade of Care – Chronic Hepatitis C
DAA: Direct-acting antivirals PBS: Pharmaceutical benefits scheme 
kirby.unsw.edu.au/report-type/annual-surveillance-report
Before DAAs became available on 
the PBS (1st March 2016)
● Relatively high proportion diagnosed, ~ 75%
● <60% of those diagnosed had 
HCV RNA testing
● 1–2% of people living with hepatitis C 
treated per annum—significantly lower 
than estimated number of new infections 
each year
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Australian Cascade of Care for Chronic Hepatitis C
Hajarizadeh B, Grebely J, Martinello M, et al. Lancet Gastroenterol Hepatol. 2016 Dec;1(4):317-327
Slide credit: Dore, G.  Kirby Institute, UNSW
Interferon-based Interferon-free
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Australian Cascade of Care for Chronic Hepatitis C
Hajarizadeh B, Grebely J, Martinello M, et al. Lancet Gastroenterol Hepatol. 2016 Dec;1(4):317-327
Slide credit: Dore, G.  Kirby Institute, UNSW
Interferon-based Interferon-free
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Australian Cascade of Care for Chronic Hepatitis C
Hajarizadeh B, Grebely J, Martinello M, et al. Lancet Gastroenterol Hepatol. 2016 Dec;1(4):317-327
Slide credit: Dore, G.  Kirby Institute, UNSW
Interferon-based Interferon-free
32,550 treated, 
~14% of all Australians 
living with chronic 
hepatitis C,
in 1st ten months 
of program
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National Viral Hepatitis Mapping Project
www.ashm.org.au/HBV/hepatitis-b-mapping-reports www.ashm.org.au/HCV/hepatitis-c-mapping-reports
Hepatitis B Mapping Project: Hepatitis C Mapping Project: 
4th National Report, 2018 1st National Report, 2018
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Mapping Chronic Hepatitis C in Australia
www.ashm.org.au/HCV/hepatitis-c-mapping-reports/
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Treatment Towards Elimination in Priority Populations
NSP: Needle and syringe programs                                                               Bartlett SR, Fox P, Cabatingan H, et al. Clinical Infectious Diseases, 12 March 2018 
Iversen J, et al. Presented at: INHSU 2017, New York, United States, September 6-8, 2017
PWID attending NSPs
● Treatment uptake in 1st 6 months higher 
among PWID (20%) than in general 
population living with HCV (14%)
● Viraemic prevalence fell from 45% 
to 32%, 2015-2016
Prison-based treatment
● HCV virtually eliminated in 3 
prisons in North Queensland by 2018
● 98% of prisoners in main prison in 
Canberra initiated treatment since April 2016
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Is Australia on Track to Achieve The WHO 2030 
Viral Hepatitis Elimination Targets?
Adapted from Kwon A, Dore G, & Grebely J.  Presented at AVHEC 10/08/2017
Modeling by the Kirby Institute 
suggests YES for hepatitis C
For hepatitis B, NO
● Substantial scale-up in diagnosis, 
care, treatment will be required
● Beyond 2030, impact of overseas 
infant vaccination programs 
will be significant 
What can these two trajectories 
tell us about steps needed for achieving elimination goals?
Treatment Scenario
WHO Target Pessimistic Intermediate Optimistic
80% reduction in new 
chronic infections
2028 2026 2023
80% of people 
living with chronic 
HCV treated
2031 2026 2021
65% reduction in 
HCV-related deaths
2029 2024 2021
Estimated year Australia Meets Each World Health 
Organization Target Compared to 2015 estimates 
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An Australian Perspective on How to Achieve Elimination
Continued focus on prevention including harm reduction needed
Reduce costs of care – consultations, diagnostics, treatment
● Universal health coverage
Community-based, primary care focus of treatment essential
Engagement with those most affected is crucial
Innovative methods to assess coverage, areas where response is 
lagging, and implement widely that which is working
Global solutions essential—no country will eliminate in isolation
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Forging Global Partnerships to Eliminate Viral Hepatitis
World Hepatitis Report 2017, World Health Organization
www.who.int/hepatitis
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CDC PUBLIC HEALTH GRAND ROUNDS 
Working Together to Eliminate the Threat of Hepatitis B and C
April 17, 2018
